×
About 80,256 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  37,305 results

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for pote...
https://doi.org/10.1016/j.ygyno.2021.02.014
Gynecologic Oncology; Arend RC, Monk BJ et. al.

Feb 27th, 2021 - Report the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinum resis...

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptoma...
https://doi.org/10.1016/j.ygyno.2021.02.002
Gynecologic Oncology; Sjoquist KM, Espinoza D et. al.

Feb 27th, 2021 - The primary aim of this study was to evaluate the activity of intraperitoneal bevacizumab (IP-bev) in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian cancer (CR-EOC) who have ceased chemotherap...

Stepping into survivorship pilot study: Harnessing mobile health and principles of beha...
https://doi.org/10.1016/j.ygyno.2021.02.023
Gynecologic Oncology; Schrier E, Xiong N et. al.

Feb 27th, 2021 - Physical activity improves physical function, quality of life, and mental health, yet fewer than 80% of ovarian cancer survivors meet activity guidelines. This pilot intervention study aimed to increase physical activity in ovarian cancer survivor...

Incidence of venous thromboembolism after standard treatment in patients with epithelia...
https://doi.org/10.1002/cam4.3797
Cancer Medicine; Shin W, Lee S et. al.

Feb 27th, 2021 - Venous thromboembolism (VTE) is a hospital-associated severe complication that may adversely affect patient prognosis. In this study, we evaluated the incidence of VTE and its risk factors in patients with epithelial ovarian cancer (EOC). We retro...

High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis...
https://doi.org/10.1371/journal.pone.0245733
PloS One; Wang H, Ye F et. al.

Feb 26th, 2021 - Recent studies have shown that the expression of ENPP1 is related to differentiation, death, dissemination and chemosensitivity of tumor cells. So far, there is no research in ovarian carcinoma. This study aimed at exploring the role of ENPP1 gene...

see more →

Guidelines  225 results

ESMO recommendations on predictive biomarker testing for homologous recombination defic...
https://doi.org/10.1016/j.annonc.2020.08.2102
Annals of Oncology : Official Journal of the European Soc... Miller RE, Leary A et. al.

Oct 2nd, 2020 - Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an oppor...

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival wi...

Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: Internatio...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294297
Gynecologic Oncology; Elledge CR, Beriwal S et. al.

Jun 21st, 2020 - To develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic. An international committee of ten experts in gynecologic radiation oncology convened to provide consensus recommenda...

see more →

Drugs  133 results see all →

Clinicaltrials.gov  40,101 results

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for pote...
https://doi.org/10.1016/j.ygyno.2021.02.014
Gynecologic Oncology; Arend RC, Monk BJ et. al.

Feb 27th, 2021 - Report the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinum resis...

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptoma...
https://doi.org/10.1016/j.ygyno.2021.02.002
Gynecologic Oncology; Sjoquist KM, Espinoza D et. al.

Feb 27th, 2021 - The primary aim of this study was to evaluate the activity of intraperitoneal bevacizumab (IP-bev) in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian cancer (CR-EOC) who have ceased chemotherap...

Stepping into survivorship pilot study: Harnessing mobile health and principles of beha...
https://doi.org/10.1016/j.ygyno.2021.02.023
Gynecologic Oncology; Schrier E, Xiong N et. al.

Feb 27th, 2021 - Physical activity improves physical function, quality of life, and mental health, yet fewer than 80% of ovarian cancer survivors meet activity guidelines. This pilot intervention study aimed to increase physical activity in ovarian cancer survivor...

Incidence of venous thromboembolism after standard treatment in patients with epithelia...
https://doi.org/10.1002/cam4.3797
Cancer Medicine; Shin W, Lee S et. al.

Feb 27th, 2021 - Venous thromboembolism (VTE) is a hospital-associated severe complication that may adversely affect patient prognosis. In this study, we evaluated the incidence of VTE and its risk factors in patients with epithelial ovarian cancer (EOC). We retro...

High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis...
https://doi.org/10.1371/journal.pone.0245733
PloS One; Wang H, Ye F et. al.

Feb 26th, 2021 - Recent studies have shown that the expression of ENPP1 is related to differentiation, death, dissemination and chemosensitivity of tumor cells. So far, there is no research in ovarian carcinoma. This study aimed at exploring the role of ENPP1 gene...

see more →

News  2,425 results

Study: Pap Test/Cervical Swab Samples Can Reveal Ovarian Cancer Biomarkers
https://www.medscape.com/viewarticle/946396

Feb 23rd, 2021 - Residual fixatives from liquid-based Pap tests and cervical swabs contain tumor-specific biomarkers for ovarian cancer, according to an analysis of proteins found in matched biospecimens from a woman with high grade serous ovarian cancer. The find...

London Team Identifies New Prognostic Biomarker for Ovarian Cancer
https://www.medscape.com/viewarticle/924968

Jan 31st, 2021 - A team of surgeons from Imperial College London have discovered a new biomarker for poor prognosis in patients with advanced high-grade serous ovarian cancer (HGSOC). In research published in the  British Journal of Cancer,  the team identified an...

Nulliparity, Not ART, Likely Raises Risk of Ovarian Cancer
https://www.medscape.com/viewarticle/944346

Jan 18th, 2021 - Women who receive ovarian stimulation for assisted reproductive technology (ART) procedures don't have an increased risk of developing ovarian cancer when compared to subfertile women who don't undergo ART, according to a new study. The results su...

NICE Approves 'Game-changing' Ovarian Cancer Drug
https://www.medscape.com/viewarticle/944178

Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...

Radiotherapy for Rectal Cancer Linked to Risk for Later Malignant Gynecological Neoplasms
https://www.medscape.com/viewarticle/943852

Jan 10th, 2021 - (Reuters Health) - Women who receive radiotherapy for rectal cancer may be at an increased risk of uterine and ovarian cancer, a new study suggests. In an analysis of information from the SEER database on more than 20,000 female patients diagnosed...

see more →

Patient Education  67 results see all →